Fall 2026, Winter 2026

BCI Strategy Intern

Posted on 8/12/2026

Deadline 9/11/26
Blackrock Neurotech

Blackrock Neurotech

51-200 employees

Develops implantable neural interfaces for communication

No salary listed

Salt Lake City, UT, USA

In Person

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
Market Research

Get referred to Blackrock Neurotech

See people who can refer or advise you

Requirements
  • Currently pursuing an undergraduate or graduate degree, specifically a Ph.D. or Master's, in biomedical, electrical, mechanical, or chemical engineering, or neuroscience.
  • Have a strong interest in neurotechnology, medical device development, or product strategy.
  • Have industry or laboratory experience focused on neural engineering or neuroscience, or experience conducting market research in a technical field.
Responsibilities
  • Conduct research on market trends, user needs, and emerging technologies to identify growth opportunities in neurotechnology and brain-computer interfaces.
  • Support cross-functional projects focused on market development and strategic positioning.
  • Contribute to initiatives that drive commercial translation of Neuralace technologies.
Desired Qualifications
  • Preferably be in the final year of the degree program or have completed the educational degree.
  • Have an understanding of what Blackrock is building with Neuralace.
  • Develop subject matter expertise in specific neurological diseases or disorders, including user priorities, patient care pathways, and the value of brain-computer interfaces.

Blackrock Neurotech develops brain-computer interface (BCI) technology. Its main offering is the Utah Array, a microelectrode device implanted in the brain to record neural signals, along with software and hardware to decode those signals so users can control computers, prosthetic limbs, or other devices. The company sells its BCI systems to research institutions and medical device companies and also provides engineering and consulting services to support implementation. Unlike many competitors that focus on noninvasive or software-only solutions, Blackrock Neurotech provides invasive neural interfaces with a complete hardware–software pipeline for recording, decoding, and using brain activity. Its goal is to help people with paralysis and other neurological disorders communicate and interact with their surroundings by restoring neural communication through implanted interfaces.

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$22.4M

Headquarters

Salt Lake City, Utah

Founded

2008

Get referred to Blackrock Neurotech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Blackrock announced MindX integration, strengthening full-stack software and AR-assisted BCI workflows.
  • Clinical visibility rose in 2026 through Wired, IEEE Spectrum, and The Scientist coverage.
  • More than 40 people already used Blackrock systems, de-risking commercial demand and training data.

What critics are saying

  • MoveAgain still lacks FDA approval in 2026; competitors can commercialize first.
  • Implantable BCI durability remains unresolved, threatening repeat surgeries, reimbursement, and physician adoption.
  • Tether controls the cap table; any crypto scandal could freeze Blackrock financing and trust.

What makes Blackrock Neurotech unique

  • Utah Array underpins 500-plus research institutions and 31 implanted patients worldwide.
  • MoveAgain won FDA Breakthrough Device designation, accelerating regulatory dialogue for implanted BCI.
  • Tether's $200 million majority stake funds commercialization without forcing near-term public-market pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Commuter Benefits

Paid Holidays

Paid Sick Leave

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

8%
Cision
Jan 16th, 2025
Most Advanced Artificial Touch For Brain-Controlled Bionic Hand

Most advanced artificial touch for brain-controlled bionic hand

PR Newswire
Aug 9th, 2024
Wvu Medicine To Host Brain-Machine Interface (Bmi) Summit Charting The Future Of Neurotechnology

Leading Neuroscientists, Technologists, Regulators, and Venture Capitalists Convening in West VirginiaMORGANTOWN, W.Va., Aug. 9, 2024 /PRNewswire/ -- West Virginia University (WVU) Medicine will host an international gathering of scientists, engineers, researchers, physicians, and industry leaders at the Brain-Machine Interface (BMI) Summit this coming weekend. Organized by Dr. Peter Konrad of WVU Medicine and Dr. Jose "Pepe" Contreras-Vidal of the University of Houston, the event is a key programming component of the National Science Foundation's (NSF) Industry-University Cooperative Research Centers (IUCRC).The conference aims to advance the accessibility and sustainability of BMI technologies for patients with neurological conditions by underscoring the need for increased collaboration across industry, government, and university systems.The BMI Summit will feature presentations and panel discussions with prominent figures from the FDA, NIH, NSF, and VA, alongside industry leaders from companies including Blackrock Neurotech, Precision Neuroscience, and Synchron. Three pioneering patients – Ian Burkhardt, Nathan Copeland, and Jen French – who have been at the forefront of BMI device trials, demonstrating the transformative potential of these technologies will be sharing their crucial patient perspective for those dealing with disabling conditions like paralysis, stroke, speech loss, vision loss, pain, and brain injury."For 20 years, we've seen incredible advancements in BMI technology, but the journey from laboratory to bedside has too often been slow and fragmented," said Dr

Intelligence360 News
May 21st, 2024
Blackrock Neurotech Raises $12.4M in Funding

Blackrock Microsystems, operating as Blackrock Neurotech, has filed a notice with the U.S. SEC to raise $12.4 million in new equity investment. CEO Marcus Gerhardt played a key role in securing the funding, which will support the company's expansion and product development. Blackrock Neurotech specializes in neural implants and brain-computer interface technology aimed at restoring function and independence to individuals with neurological disorders.

Swipeline
Apr 30th, 2024
Tether Invests $200M in Blackrock Neurotech

Tether, a cryptocurrency company, has invested $200 million in US-based Blackrock Neurotech, a competitor to Elon Musk's Neuralink. Blackrock Neurotech develops brain chips aimed at helping individuals with neurological diseases regain abilities such as walking, talking, hearing, seeing, and feeling. The technology also enables users to control prosthetic limbs through thought and experience sensory feedback, enhancing interaction with robotic arms. The investment will help commercialize and launch the technology, already used by 40 people.

PYMNTS
Apr 29th, 2024
Tether Buys Majority of Blackrock Neurotech for $200M

Tether has invested $200 million to acquire a majority stake in Blackrock Neurotech, a leader in brain-computer-interface technology. This partnership aims to accelerate the development and commercialization of BCI technologies, which allow direct brain communication with devices, enhancing functions like operating robotic arms and driving cars. This move aligns with Tether's strategy to diversify its portfolio and invest in transformative technologies.